insights_auto
Outlook: 29.7% bullish·8.1% bearish
Go to analysischevron_right
NVO:NYSE
Novo Nordisk A/S
$38.12
arrow_upward
+0.16%(+0.060) 1D
$38.80
arrow_upward
+1.78% (+0.68)todayPre-market
Closed: Oct 14, 4:00:04 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVO...
Open
$37.90
High
$38.42
Low
$37.90
Mkt. cap
130.07B
Avg. vol.
13.28M
Volume
337.31K
Dividend
4.71%
Quarterly dividend
$0.45
Ex-dividend date
Aug 14, 2026
P/E ratio
9.72
52-wk high
$64.16
52-wk low
$35.12
EPS
$3.92
Beta
0.75
Shares outstanding
3.39B
No. of employees
67K
Open
$37.90
High
$38.42
Low
$37.90
Mkt. cap
130.07B
Avg. vol.
13.28M
Volume
337.31K
Dividend
4.71%
Quarterly dividend
$0.45
Ex-dividend date
Aug 14, 2026
P/E ratio
9.72
52-wk high
$64.16
52-wk low
$35.12
EPS
$3.92
Beta
0.75
Shares outstanding
3.39B
No. of employees
67K
News stories
From web sources and news partners
ad-hoc-news.de
·
2 hours ago
Novo Nordisk stock gains 1.12 percent ahead of November 4 results
Yahoo Finance
·
15 hours ago
Novo Nordisk (NVO) Could Be 63% Undervalued Following Its Share Buyback
Benzinga
·
15 hours ago
QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom
Simply Wall Street
·
16 hours ago
Novo Nordisk (NVO) Could Be 57% Undervalued As Buyback Puts Fair Value In Focus
Profile
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees66.7K
Founded1923
HeadquartersBagsværd, Capital Region of Denmark, Denmark
SectorPharmaceutical industry
Websitenovonordisk.com